AD

Award Number: W81XWH-13-1-0053

TITLE: Application of FDA-Approved Memantine and Newer NitroMemantine Derivatives to Treat Neurological Manifestations in Rodent Models of Tuberous Sclerosis Complex

PRINCIPAL INVESTIGATOR: Stuart Lipton

CONTRACTING ORGANIZATION: Sanford-Burnham Medical Research Institute

REPORT DATE: T æ 2014

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

### DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

Pail: experts duces by the defined in thermaline is employed by the processing relations and employed in the processing discount in provide the second employed in the processing discount in provide the second employed in the processing discount in provide the second employed in the processing discount in provide the second employed in the processing discount in provide the second employed in the processing discount in provide the second employed in the provide interval in the provide interval in the provide interval in the provide interval i	F	REPORT DOC		N PAGE		Form Approved OMB No. 0704-0188	
Ar al: 2014       On Lag       O1 May 2013 - 20 Aprig 2014         A TITLE AND SUBTITLE       Application of FDA-Approved Memantine and Newer NirroMemantine Derivatives to Treat       So CONTRACT NUMBER         Neurological Manifestations in Rodent Models of Tuberous Scierosis Complex       Volt XWH-13-1-0053       So CONTRACT NUMBER         Neurological Manifestations in Rodent Models of Tuberous Scierosis Complex       So Contract Number       W31XWH-13-1-0053         6. AUTHORIS)       So FROSCHAM ELEMENT NUMBER       So FROSCHAM ELEMENT NUMBER         7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)       So TASK NUMBER       St WORK UNIT NUMBER         7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)       So FROSCHIMONITOR'S ACRONYM(S)       NUMBER         10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       II. SPONSOR/MONITOR'S ACRONYM(S)       II. SPONSOR/MONITOR'S ACRONYM(S)         12. SITTIBUTION / AVAILABILITY STATEMENT       Approved for Public Release; Distribution Unlimited       II. SPONSOR/MONITOR'S ACRONYM(S)         13. SUPPLEMENTARY NOTES       II. SUPLEMENTARY NOTES       III. SPONSOR/MONITOR'S ACRONYM(S)       III. SPONSOR/MONITOR'S ACRONYM(S)         14. ABSTRACT       Number Reliated by Tuberous Scierosis Complex (TSC) is affected by intellectual and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective threapies for early posinatal or even emphasing and innorecomplexitons of the N- methyl-b appartiate t	data needed, and completing this burden to Department of I 4302. Respondents should be	and reviewing this collection of in Defense, Washington Headquart e aware that notwithstanding any	nformation. Send comments rega ers Services, Directorate for Infor other provision of law, no person	arding this burden estimate or an mation Operations and Reports ( n shall be subject to any penalty f	y other aspect of this co 0704-0188), 1215 Jeffe	llection of information, including suggestions for reducing rson Davis Highway, Suite 1204, Arlington, VA 22202-	
4. TTLE AND SUBTITLE       S. CONTRACT NUMBER         Application of PDA-Approved Memantine and Newer NitroMemantine Derivatives to Treat       S. CONTRACT NUMBER         Neurological Manifestations in Rodent Models of Tuberous Sclerosis Complex       S. CONTRACT NUMBER         C. AUTHOR(6)       S. GRAM ELEMENT NUMBER         E. AUTHOR(6)       S. GRAM ELEMENT NUMBER         E. Mail: sliniten@kamfordhumhum.org       S. PORGAM ELEMENT NUMBER         E. Mail: sliniten@kamfordhumhum.org       S. PERFORMING ORGANIZATION NARE(5) AND ADDRESS(ES)         S. anford-Burnham Medical Research Institute       S. PERFORMING ORGANIZATION REPORT         La Jolla, CA 92037       S. PERFORMING ORGANIZATION REPORT         S. SPONSORING I MONITORING AGENCY NAME(S) AND ADDRESS(ES)       S. PERFORMING ORGANIZATION REPORT         LS. Army Medical Research and Materiel Command       Fort Detrick, Maryland 21702-5012         10. SPONSOR/MONITOR'S REPORT       NUMBER         13. SUPPLEMENTARY NOTES       Saffected by intellectual and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective therapies for early postratal or even embryonic treatment of these neurological amarifestations. Towards this goal, we propose to investigate if administration of the FDA-approved drug Memantine, an uncompetitive/fast Grif rate antagonist of the A-methylo asparate-byce glutamate receptor, and its improved derivative, NitroMemantine, emeiorate neurological complications in mouse models of TSC. During Yar 01 of the	1. REPORT DATE	2	2. REPORT TYPE		-		
Application of FDA-Approved Memantine and Newer NitroMemantine Derivatives to Treat       W81XWH-13-1-0053         Neurological Manifestations in Rodent Models of Tuberous Sclerosis Complex       B. GRANT NUMBER         Standard Component Sclerosis Complex       Sc. PROGRAM ELEMENT NUMBER         6. AUTHOR(6)       E.Mail: slipton@sanferdburnham.org       5. GRANT RUMBER         E-Mail: slipton@sanferdburnham.org       5. WORK UNIT NUMBER       5. TASK NUMBER         Sanford-Burnham Medical Research Institute       B. PERFORMING ORGANIZATION REPORT       NUMBER         La Jolla, CA 92037       II. SPONSORING / MONITORING AGENCY NAME(6) AND ADDRESS(ES)       II. SPONSOR/MONITOR'S ACRONYM(S)         S. SPONSORING / MONITORING AGENCY NAME(6) AND ADDRESS(ES)       II. SPONSOR/MONITOR'S ACRONYM(S)       II. SPONSOR/MONITOR'S ACRONYM(S)         V.S. Army Medical Research and Materiel Command       Fort Detrick, Maryland 21702-5012       II. SPONSOR/MONITOR'S REPORT NUMBER         13. SUPPLEMENTARY NOTES       II. SPONSOR/MONITOR'S REPORT NUMBER       II. SPONSOR/MONITOR'S REPORT NUMBER         14. ABSTRACT       The quality of life for those afflicted by Tuberous Sclerosis Complex (TSC) is affected by intellectual and neurological disabilities mediated in part by excessive glutamaterics activity in the brain. It is important to develop rational and effective threayies for carly opstratal or yee uprovoic treatment of these neurological manifestations. Towards this Goal, we propose to investigate if administration of the FDA-approved drug Memantine, an uncompetitive/fast off			Annual				
Neurological Munifestations in Rodent Models of Tuberous Sclerosis Complex         E. GRATY TUMBER           8. AUTHOR(5)         5d. PROGRAM ELEMENT NUMBER           1. Lipton, Stuart A.         5d. PROJECT NUMBER           6. AUTHOR(5)         5d. PROJECT NUMBER           1. Lipton, Stuart A.         5d. TASK NUMBER           6. AUTHOR(5)         5d. PROJECT NUMBER           5. SPONSORING ORGANIZATION NAME(5) AND ADDRESS(ES)         8. PERFORMING ORGANIZATION REPORT           Sanford-Burnham Medical Research Institute         8. PERFORMING ORGANIZATION REPORT           10. S. Army Medical Research and Materiel Command         10. SPONSOR/MONITOR'S ACRONYM(5)           11. SPONSOR/MOLITOR'S ACRONYM(5)         11. SPONSOR/MONITOR'S ACRONYM(5)           12. DISTRIBUTION / AVAILABILITY STATEMENT         NUMBER(5)           13. SUPPLEMENTARY NOTES         11. SPONSOR/MONITOR'S REPORT           14. ABSTRACT         The quality of life for those afflicted by Tuberous Sclerosis Complex (TSC) is affected by intellectual and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective threapies for early postnatal or even embryonic treatment of these neurological manifestations. Towards this goal, we propose to investigate if administration of the FDA-approved drug. Memantine, an uncompetitive/fast df-rate antagorist of the M- methy-to-aspartale-type glutamater receptor, and its imported of TS2 <sup>C</sup> mice with Memantine Bingrad and effective threrapies for early postnatal or even embryonic treatmen			ne and Newer NitroMe	emantine Derivatives			
WB1XWH13-1-0053           5c. PROGRAM ELEMENT NUMBER           Lipton, Stuart A.           E-Mail: slipton@camfordhumlam.org           7. PERFORME ORGANIZATION NAME(S) AND ADDRESS(ES)           Sanford-Burnham Mcdical Research Institutc           La Jolla, CA 92037           9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)           U.S. Army Medical Research Institutc           La Jolla, CA 92037           10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)           U.S. Army Medical Research and Materiel Command           Fort Detrick, Maryland 21702-5012           11. SPONSOR/MONITOR'S REPORT NUMBER           13. SUPPLEMENTARY NOTES           14. ABSTRACT           The quality of life for those afflicted by Tuberous Sclerosis Complex (TSC) is affected by intellectual and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective therapies for early postnatia or even embryonic treatment of these neurological manifestations. Towards this goal, we propose to investigate if administration of the FDA-approved drug, Memantine, an uncompetitive/fast dfr-fast antagonist of the A- methylo-aspartate-type glutamate receptor, and its improved derivative, NitroMemantine, ameliorate neurological complications in mouse models of TSC. During Year 01 of the grant, we obtained favorable results for Memantine sites in TSc2 <sup>TM</sup> ince. With Memantine sites in TSc2 <sup>TM</sup> ince. With Memantine sites in TSc2 <sup>TM</sup> ince. With Memantine active of hippocampal memory, in Year 02, we plan to further validate and	**					GRANT NUMBER	
AUTHOR(S) Lipton, Stuart A.     Sd. PROJECT NUMBER     Signon Start A.     Sd. PROST NUMBER     Start A.     Start	C			1			
Lipton, Stuart A.       5c. TASK NUMBER         E-Mail: slipton@isanfordbumham.org       5c. WORK UNIT NUMBER         7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)       8. PERFORMING ORGANIZATION REPORT         Sanford-Burnham Medical Research Institute       1.         La Jolla, CA 92037       1.         S. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       1.         S. Army Medical Research and Materiel Command       1.         Fort Detrick, Maryland 21702-5012       11. SPONSORIMONITOR'S ACRONYM(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT         Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES         14. ABSTRACT         The quality of life for those afflicted by Tuberous Sclerosis Complex (TSC) is affected by intellectual and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective therapies for early postnatal or even embryonic treatment of these neurological manifestations. Towards this goal, we propose on eveloting davorable results for Memantine on electrophysiological and neurobehavioral tests in Tsc2 <sup>m</sup> mice. Treatment of Tsc2 <sup>m</sup> mice with Memantine in on electrophysiological and neurobehavioral tests in Tsc2 <sup>m</sup> mice. Treatment of Tsc2 <sup>m</sup> mice with Memantine in proved long-term potentiation (LTP), an electrical correlate of leagond memory. In the CAA tregion of the homenatine on electrophysiological and neurobehavioral tests in Tsc2 <sup>m</sup> mice. Treatment of Tsc2 <sup>m</sup> mice with Memantine inon ecoles of TSC. During Year OI of the gability to locate the pl					5c.	PROGRAM ELEMENT NUMBER	
E-Mail: slipton@sanfordhumham.org       5e. TASK NUMBER         F.PERFORMING ONGANIZATION NAME(S) AND ADDRESS(ES)       5f. WORK UNIT NUMBER         Sanford-Burnham Medical Research Institute       1         La Jolla, CA 92037       10. SPONSORING ONGANIZATION RAME(S) AND ADDRESS(ES)         S. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       10. SPONSOR/MONITOR'S ACRONYM(S)         U.S. Army Medical Research and Materiel Command       11. SPONSOR/MONITOR'S ACRONYM(S)         Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S REPORT         NUMBER(S)       11. SPONSOR/MONITOR'S REPORT         14. ABSTRACT       The quality of life for those afflicted by Tuberous Sclerosis Complex (TSC) is affected by intellectual and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective therapies for early postnatal or even embryonic treatment of Tsc2'' mice with Memantine on the Daparoved drug. Memantine, an uncompetitive/fast off-rate antagonist of the A-Memethyl-c-aspartate-type glutamate receptor					5d.	PROJECT NUMBER	
E-Mail:       shipton@sanfordbumham.org         7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)       Sanford-Burnham Medical Research Institute         La Jolla, CA 92037       8. PERFORMING ORGANIZATION REPORT         S.SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       10. SPONSOR/MONITOR'S ACRONYM(S)         U.S. Army Medical Research and Materiel Command       11. SPONSOR/MONITOR'S ACRONYM(S)         Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S ACRONYM(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT       NUMBER(S)         Approved for Public Release; Distribution Unlimited       13. SUPPLEMENTARY NOTES         14. ABSTRACT       The quality of life for those afflicted by Tuberous Sclerosis Complex (TSC) is affected by intellectual and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective therapies for early postnatal or even embryonic treatement of these neurological manifestations. Towards this goal, we propose to investigate if administration of the FDA-approved drug, Memantine, an uncompetitive/fast off-rate antagonist of the N-methyl-D-aspartate-type glutamate receptor, and its improved derivative, NitroMemantine, ameliorate neurological complexitional in event to the SC. During Year 01 of the grant, we obtained favorable results for Memantine on electrophysiological and neurobehavioral tests in 75c2 <sup>27</sup> mice. Treatment of 7sc2 <sup>27</sup> mice with Memantine eitorproved four-thippocampla and memory. In Year 02, we plan to further validate and extend our findings with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an a	Lipton, Stuart A.				5e.	TASK NUMBER	
1. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)       8. PERFORMING ORGANIZATION REPORT         Sanford-Burnham Medical Research Institute       1. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)         U.S. Army Medical Research and Materiel Command       10. SPONSOR/MONITOR'S ACRONYM(S)         Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S ACRONYM(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT         Approved for Public Release, Distribution Unlimited         13. SUPPLEMENTARY NOTES         14. ABSTRACT         The quality of life for those afflicted by Tuberous Sclerosis Complex (TSC) is affected by intellectual and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective therapies for early postnatal or even embryonic treatment of these neurological manifestations. Towards this goal, we propose to investigate if administration of the FDA-approved drug, Memantine, an uncompetitive/Fast off-rate antagonist of the N-methyl-baspratte-type glutamate receptor, and its improved heravity, NITKOMemantine, amelionate neurological complications in mouse models of TSC. During Year 01 of the grant, we obtained favorable results for Memantine on electrophysiological and neurobehavioral tests in <i>Tsc2**</i> mice. Treatment of <i>Tsc2**</i> mice with Memantine improved long-term potentiation (LTP), an electrical correlate of learning and memory. In Year 02, we plat to turber validate and extend our findings with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an advantage over Memantine in TSC model mice, as we have					5f. \	WORK UNIT NUMBER	
Sanford-Burnham Medical Research Institute       NUMBER         La Jolla, CA 92037       II. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       II. SPONSOR/MONITOR'S ACRONYM(S)         J.S. Army Medical Research and Materiel Command       Fort Detrick, Maryland 21702-5012       II. SPONSOR/MONITOR'S ACRONYM(S)         I.S. DISTRIBUTION / AVAILABILITY STATEMENT       Approved for Public Release; Distribution Unlimited       III. SPONSOR/MONITOR'S REPORT         I.S. SUPPLEMENTARY NOTES       III. SPONSOR/MONITOR'S method and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective therapies for early postnatal or even embryonic treatment of these neurological manifestations. Towards this goal, we propose to investigate if administration of the FDA-approved drug, Memantine, an uncompetitive/fast off-rate antagonist of the <i>N</i> -methyl-D-aspartate-type glutamaterceptor, and its improved derivative, NitroMemantine, ameliorate neurological complications in mouse models of TSC. During Year 01 of the grant, we obtained favorable results for Memantine on electrophylogicigal and neurobehavioral tests in TSC <sup>2+</sup> mice with Memantine on metroved long-term potentiation (LTP), an electrical correlate of learning and memory. In the CA1 region of the hippocampus. Additionally, treatment of TSC <sup>2+</sup> mice with Memantine showed a trend towards restoration of the ability to locate the platform in the Morris water maze, a neurobehavioral test of hippocampual memory. In Year 02, we plan to further validate and extend our findings with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an advantage over Memantine in TSC model mice, as we have previously demonstrated in other neurological	E-Mail: slipton@sa	nfordburnham.org					
Samous-Bullmann Medical Research misinule       Image: Comparison of the second s					-		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       10. SPONSOR/MONITOR'S ACRONYM(S)         U.S. Army Medical Research and Materiel Command       11. SPONSOR/MONITOR'S ACRONYM(S)         Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S REPORT         NUMBER(S)       11. SPONSOR/MONITOR'S REPORT         12. DISTRIBUTION / AVAILABILITY STATEMENT       Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES       14. ABSTRACT         The quality of life for those afflicted by Tuberous Sclerosis Complex (TSC) is affected by intellectual and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective therapies for early postnatal or even embryonic treatment of these neurological manifestations. Towards this goal, we propose to investigate if administration of the FDA-approved drug, Memantine, an uncompetitive/fast off-rate antagonist of the <i>N</i> -methyl-D-aspartate-type glutamate receptor, and its improved derivative, NitroMemantine ameliorate neurological complications in mouse models of TSC. During Year 01 of the grant, we obtained favorable results for Memantine on electrophysiological and neurobehavioral tests in <i>Tsc2</i> <sup>**</sup> mice. Treatment of <i>Tsc2</i> <sup>**</sup> mice with Memantine on electrophysiological and neurobehavioral tests in <i>Tsc2</i> <sup>**</sup> mice. Treatment of <i>Tsc2</i> <sup>**</sup> mice with Memantine in the Morris water maze, a neurobehavioral test of hippocampal memory. In Year 02, we plan to further validate and extend our findings with Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders.       15. SUBJECT TERMS         Excensive glutamatergic activity, Extrasynaptic NMDA recepto	Santora-Burnnai	n Medical Resear	ch Institute			OMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       10. SPONSOR/MONITOR'S ACRONYM(S)         U.S. Army Medical Research and Materiel Command       11. SPONSOR/MONITOR'S ACRONYM(S)         Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S REPORT         NUMBER(S)       11. SPONSOR/MONITOR'S REPORT         12. DISTRIBUTION / AVAILABILITY STATEMENT       Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES       14. ABSTRACT         The quality of life for those afflicted by Tuberous Sclerosis Complex (TSC) is affected by intellectual and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective therapies for early postnatal or even embryonic treatment of these neurological manifestations. Towards this goal, we propose to investigate if administration of the FDA-approved drug, Memantine, an uncompetitive/fast off-rate antagonist of the <i>N</i> -methyl-D-aspartate-type glutamate receptor, and its improved derivative, NitroMemantine ameliorate neurological complications in mouse models of TSC. During Year 01 of the grant, we obtained favorable results for Memantine on electrophysiological and neurobehavioral tests in <i>Tsc2</i> <sup>**</sup> mice. Treatment of <i>Tsc2</i> <sup>**</sup> mice with Memantine on electrophysiological and neurobehavioral tests in <i>Tsc2</i> <sup>**</sup> mice. Treatment of <i>Tsc2</i> <sup>**</sup> mice with Memantine in the Morris water maze, a neurobehavioral test of hippocampal memory. In Year 02, we plan to further validate and extend our findings with Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders.       15. SUBJECT TERMS         Excensive glutamatergic activity, Extrasynaptic NMDA recepto	La Jolla CA 920	)37					
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S REPORT NUMBER(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited       11. SPONSOR/MONITOR'S REPORT NUMBER(S)         13. SUPPLEMENTARY NOTES       13. SUPPLEMENTARY NOTES         14. ABSTRACT The quality of life for those afflicted by Tuberous Sclerosis Complex (TSC) is affected by intellectual and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective therapies for early postnatal or even embryonic treatment of these neurological manifestations. Towards this goal, we propose to investigate if administration of the FDA-approved drug, Memantine, an uncompetitive/fast off-rate antagonist of the <i>N</i> - methyl-D-aspartate-type glutamate receptor, and its improved derivative, NitroMemantine, ameliorate neurological complications in mouse models of TSC. During Year 01 of the grant, we obtained favorable results for Memantine on electrophysiological and neurobehavioral tests in <i>Tsc2<sup>1//</sup></i> mice. Treatment of <i>Tsc2<sup>1//</sup></i> mice with Memantine on electrophysiological and neurobehavioral tests in <i>Tsc2<sup>1//</sup></i> mice. Treatment of <i>Tsc2<sup>1//</sup></i> mice with Memantine of the hippocampus. Additionally, treatment of <i>Tsc2<sup>1//</sup></i> mice with Memantine showed a trend towards restoration of the ability to locate the platform in the Morris water maze, a neurobehavioral test of hippocampal memory. In Year 02, we plan to further validate and extend our findings with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an advantage over Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders.       15. SUBJECT TERMS Excessive glutamatergic activity, Extrasynaptic NMDA							
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S REPORT NUMBER(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited       11. SPONSOR/MONITOR'S REPORT NUMBER(S)         13. SUPPLEMENTARY NOTES       13. SUPPLEMENTARY NOTES         14. ABSTRACT The quality of life for those afflicted by Tuberous Sclerosis Complex (TSC) is affected by intellectual and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective therapies for early postnatal or even embryonic treatment of these neurological manifestations. Towards this goal, we propose to investigate if administration of the FDA-approved drug, Memantine, an uncompetitive/fast off-rate antagonist of the <i>N</i> - methyl-D-aspartate-type glutamate receptor, and its improved derivative, NitroMemantine, ameliorate neurological complications in mouse models of TSC. During Year 01 of the grant, we obtained favorable results for Memantine on electrophysiological and neurobehavioral tests in <i>Tsc2<sup>1//</sup></i> mice. Treatment of <i>Tsc2<sup>1//</sup></i> mice with Memantine on electrophysiological and neurobehavioral tests in <i>Tsc2<sup>1//</sup></i> mice. Treatment of <i>Tsc2<sup>1//</sup></i> mice with Memantine of the hippocampus. Additionally, treatment of <i>Tsc2<sup>1//</sup></i> mice with Memantine showed a trend towards restoration of the ability to locate the platform in the Morris water maze, a neurobehavioral test of hippocampal memory. In Year 02, we plan to further validate and extend our findings with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an advantage over Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders.       15. SUBJECT TERMS Excessive glutamatergic activity, Extrasynaptic NMDA							
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S REPORT NUMBER(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited       11. SPONSOR/MONITOR'S REPORT NUMBER(S)         13. SUPPLEMENTARY NOTES       13. SUPPLEMENTARY NOTES         14. ABSTRACT The quality of life for those afflicted by Tuberous Sclerosis Complex (TSC) is affected by intellectual and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective therapies for early postnatal or even embryonic treatment of these neurological manifestations. Towards this goal, we propose to investigate if administration of the FDA-approved drug, Memantine, an uncompetitive/fast off-rate antagonist of the <i>N</i> - methyl-D-aspartate-type glutamate receptor, and its improved derivative, NitroMemantine, ameliorate neurological complications in mouse models of TSC. During Year 01 of the grant, we obtained favorable results for Memantine on electrophysiological and neurobehavioral tests in <i>Tsc2<sup>1//</sup></i> mice. Treatment of <i>Tsc2<sup>1//</sup></i> mice with Memantine on electrophysiological and neurobehavioral tests in <i>Tsc2<sup>1//</sup></i> mice. Treatment of <i>Tsc2<sup>1//</sup></i> mice with Memantine of the hippocampus. Additionally, treatment of <i>Tsc2<sup>1//</sup></i> mice with Memantine showed a trend towards restoration of the ability to locate the platform in the Morris water maze, a neurobehavioral test of hippocampal memory. In Year 02, we plan to further validate and extend our findings with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an advantage over Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders.       15. SUBJECT TERMS Excessive glutamatergic activity, Extrasynaptic NMDA				S(FS)	10		
Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S REPORT NUMBER(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES         14. ABSTRACT The quality of life for those afflicted by Tuberous Sclerosis Complex (TSC) is affected by intellectual and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective therapies for early postnatal or even embryonic treatment of these neurological manifestations. Towards this goal, we propose to investigate if administration of the FDA-approved drug, Memantine, an uncompetitive/fast off-rate antagonist of the <i>N</i> - methyl-D-appartate-type glutamate receptor, and its improved derivative, NitroMemantine, ameliorate neurological complications in mouse models of TSC. During Year 01 of the grant, we obtained favorable results for Memantine on electrophysiological and neurobehavioral tests in Tsc2 <sup>1+</sup> mice. Treatment of Tsc2 <sup>2+</sup> mice with Memantine improved long-term potentiation (LTP), an electrical correlate of learning and memory, in the CA1 region of the hippocampus. Additionally, treatment of Tsc2 <sup>2+</sup> mice with Memantine showed a trend towards restoration of the ability to locate the platform in the Morris water maze, a neurobehavioral test of hippocampal memory. In Year 02, we plan to further validate and extend our findings with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an advantage over Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders.       19a. NAME OF RESPONSIBLE PERSON USAMRMC         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       19a. NAME OF RESPONSIBLE PERSON USAMRMC       19a. NAME OF				5(23)	10.		
NUMBER(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT         Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES         14. ABSTRACT         The quality of life for those afflicted by Tuberous Sclerosis Complex (TSC) is affected by intellectual and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective therapies for early postnatal or even embryonic treatment of these neurological manifestations. Towards this goal, we propose to investigate if administration of the FDA-approved drug, Memantine, an uncompetitive/fast off-rate antagonist of the <i>N</i> -methyl-o-aspartate-type glutamate receptor, and its improved derivative, NitroMemantine, ameliorate neurological complications in mouse models of TSC. During Year 01 of the grant, we obtained favorable results for Memantine on electrophysiological and neurobehavioral tests in <i>Tsc2<sup>1+</sup></i> mice. Treatment of <i>Tsc2<sup>2+-</sup></i> mice with Memantine improved long-term potentiation (LTP), an electrical correlate of learning and memory. In the CA1 region of the hippocampus. Additionally, treatment of <i>Tsc2<sup>2+-</sup></i> mice with Memantine showed a trend towards restoration of the ability to locate the platform in the Morris water maze, a neurobehavioral test of hippocampal memory. In Year 02, we plan to further validate and extend our findings with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an advantage over Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders.       15. SUBJECT TERMS         ISCURT TERMS         Inteerevint teams of <i>Secons</i> (Singer Singerevious)	-						
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES         14. ABSTRACT The quality of life for those afflicted by Tuberous Sclerosis Complex (TSC) is affected by intellectual and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective therapies for early postnatal or even embryonic treatment of these neurological manifestations. Towards this goal, we propose to investigate if administration of the FDA-approved drug, Memantine, an uncompetitive/fast off-rate antagonist of the <i>N</i> - methyl-o-aspartate-type glutamate receptor, and its improved derivative, NitroMemantine, ameliorate neurological complications in mouse models of TSC. During Year 01 of the grant, we obtained favorable results for Memantine on electrophysiological and neurobehavioral tests in <i>Tsc2<sup>1/-</sup></i> mice. Treatment of <i>Tsc2<sup>1/-</sup></i> mice with Memantine improved long-term potentiation (LTP), an electrical correlate of learning and memory, in the CA1 region of the hippocampus. Additionally, treatment of <i>Tsc2<sup>1/-</sup></i> mice with Memantine showed a trend towards restoration of the ability to locate the platform in the Morris water maze, a neurobehavioral test of hippocampal memory. In Year 02, we plan to further validate and extend our findings with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an advantage over Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders.         15. SUBJECT TERMS Excessive glutamatergic activity, Extrasynaptic NMDA receptors, Uncompetitive antagonist of NMDA receptors, Memantine, NitroMemantine       18. NUMBER USAMRMC         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       18. NUMBER USAMR	-				11.	SPONSOR/MONITOR'S REPORT	
Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES         14. ABSTRACT         The quality of life for those afflicted by Tuberous Sclerosis Complex (TSC) is affected by intellectual and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective therapies for early postnatal or even embryonic treatment of these neurological manifestations. Towards this goal, we propose to investigate if administration of the FDA-approved drug, Memantine, an uncompetitive/fast off-rate antagonist of the <i>N</i> -methyl-D-aspartate-type glutamate receptor, and its improved derivative, NitroMemantine, ameliorate neurological complications in mouse models of TSC. During Year 01 of the grant, we obtained favorable results for Memantine on electrophysiological and neurobehavioral tests in <i>Tsc2<sup>+/-</sup></i> mice. Treatment of <i>Tsc2<sup>+/-</sup></i> mice with Memantine improved long-term potentiation (LTP), an electrical correlate of learning and memory. In the CA1 region of the hippocampus. Additionally, treatment of <i>Tsc2<sup>+/-</sup></i> mice with Memantine showed a trend towards restoration of the ability to locate the platform in the Morris water maze, a neurobehavioral test of hippocampal memory. In Year 02, we plan to further validate and extend our findings with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an advantage over Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders.         15. SUBJECT TERMS         Excessive glutamatergic activity, Extrasynaptic NMDA receptors, Uncompetitive antagonist of NMDA receptors, Memantine, NitroMemantine         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       19. NAME OF RESPONSIBLE P						NUMBER(S)	
Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES         14. ABSTRACT         The quality of life for those afflicted by Tuberous Sclerosis Complex (TSC) is affected by intellectual and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective therapies for early postnatal or even embryonic treatment of these neurological manifestations. Towards this goal, we propose to investigate if administration of the FDA-approved drug, Memantine, an uncompetitive/fast off-rate antagonist of the <i>N</i> -methyl-D-aspartate-type glutamate receptor, and its improved derivative, NitroMemantine, ameliorate neurological complications in mouse models of TSC. During Year 01 of the grant, we obtained favorable results for Memantine on electrophysiological and neurobehavioral tests in <i>Tsc2<sup>+/-</sup></i> mice. Treatment of <i>Tsc2<sup>+/-</sup></i> mice with Memantine improved long-term potentiation (LTP), an electrical correlate of learning and memory. In the CA1 region of the hippocampus. Additionally, treatment of <i>Tsc2<sup>+/-</sup></i> mice with Memantine showed a trend towards restoration of the ability to locate the platform in the Morris water maze, a neurobehavioral test of hippocampal memory. In Year 02, we plan to further validate and extend our findings with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an advantage over Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders.         15. SUBJECT TERMS         Excessive glutamatergic activity, Extrasynaptic NMDA receptors, Uncompetitive antagonist of NMDA receptors, Memantine, NitroMemantine         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       19. NAME OF RESPONSIBLE P			ACNT				
13. SUPPLEMENTARY NOTES         14. ABSTRACT         The quality of life for those afflicted by Tuberous Sclerosis Complex (TSC) is affected by intellectual and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective therapies for early postnatal or even embryonic treatment of these neurological manifestations. Towards this goal, we propose to investigate if administration of the FDA-approved drug, Memantine, an uncompetitive/fast off-rate antagonist of the <i>N</i> -methyl-D-aspartate-type glutamate receptor, and its improved derivative, NitroMemantine, ameliorate neurological complications in mouse models of TSC. During Year 01 of the grant, we obtained favorable results for Memantine on electrophysiological and neurobehavioral tests in <i>Tsc2<sup>+/-</sup></i> mice. Treatment of <i>Tsc2<sup>+/-</sup></i> mice with Memantine improved long-term potentiation (LTP), an electrical correlate of learning and memory, in the CA1 region of the hippocampus. Additionally, treatment of <i>Tsc2<sup>-/-</sup></i> mice with Memantine showed a trend towards restoration of the ability to locate the platform in the Morris water maze, a neurobehavioral test of hippocampal memory. In Year 02, we plan to further validate and extend our findings with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an advantage over Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders.         15. SUBJECT TERMS         Excessive glutamatergic activity, Extrasynaptic NMDA receptors, Uncompetitive antagonist of NMDA receptors, Memantine, NitroMemantine         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF PAGES       19a. NAME OF RESPONSIBLE PERSON USAMRMC         a. REPORT       b. ABSTRACT <td colspan="6"></td>							
14. ABSTRACT         The quality of life for those afflicted by Tuberous Sclerosis Complex (TSC) is affected by intellectual and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective therapies for early postnatal or even embryonic treatment of these neurological manifestations. Towards this goal, we propose to investigate if administration of the FDA-approved drug, Memantine, an uncompetitive/fast off-rate antagonist of the <i>N</i> -methyl-D-aspartate-type glutamate receptor, and its improved derivative, NitroMemantine, ameliorate neurological complications in mouse models of TSC. During Year 01 of the grant, we obtained favorable results for Memantine on electrophysiological and neurobehavioral tests in <i>Tsc2<sup>+/-</sup></i> mice. Treatment of <i>Tsc2<sup>+/-</sup></i> mice with Memantine improved long-term potentiation (LTP), an electrical correlate of learning and memory, in the CA1 region of the hippocampus. Additionally, treatment of <i>Tsc2<sup>+/-</sup></i> mice with Memantine showed a trend towards restoration of the ability to locate the platform in the Morris water maze, a neurobehavioral test of hippocampal memory. In Year 02, we plan to further validate and extend our findings with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an advantage over Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders.         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       18. NUMBER OF RESPONSIBLE PERSON USAMRMC.         a. REPORT       b. ABSTRACT       c. THIS PAGE       18. NUMBER (include aree)							
14. ABSTRACT         The quality of life for those afflicted by Tuberous Sclerosis Complex (TSC) is affected by intellectual and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective therapies for early postnatal or even embryonic treatment of these neurological manifestations. Towards this goal, we propose to investigate if administration of the FDA-approved drug, Memantine, an uncompetitive/fast off-rate antagonist of the <i>N</i> -methyl-D-aspartate-type glutamate receptor, and its improved derivative, NitroMemantine, ameliorate neurological complications in mouse models of TSC. During Year 01 of the grant, we obtained favorable results for Memantine on electrophysiological and neurobehavioral tests in <i>Tsc2<sup>+/-</sup></i> mice. Treatment of <i>Tsc2<sup>+/-</sup></i> mice with Memantine improved long-term potentiation (LTP), an electrical correlate of learning and memory, in the CA1 region of the hippocampus. Additionally, treatment of <i>Tsc2<sup>+/-</sup></i> mice with Memantine showed a trend towards restoration of the ability to locate the platform in the Morris water maze, a neurobehavioral test of hippocampal memory. In Year 02, we plan to further validate and extend our findings with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an advantage over Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders.         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       18. NUMBER OF RESPONSIBLE PERSON USAMRMC.         a. REPORT       b. ABSTRACT       c. THIS PAGE       18. NUMBER (include aree)							
14. ABSTRACT         The quality of life for those afflicted by Tuberous Sclerosis Complex (TSC) is affected by intellectual and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective therapies for early postnatal or even embryonic treatment of these neurological manifestations. Towards this goal, we propose to investigate if administration of the FDA-approved drug, Memantine, an uncompetitive/fast off-rate antagonist of the <i>N</i> -methyl-D-aspartate-type glutamate receptor, and its improved derivative, NitroMemantine, ameliorate neurological complications in mouse models of TSC. During Year 01 of the grant, we obtained favorable results for Memantine on electrophysiological and neurobehavioral tests in <i>Tsc2<sup>+/-</sup></i> mice. Treatment of <i>Tsc2<sup>+/-</sup></i> mice with Memantine improved long-term potentiation (LTP), an electrical correlate of learning and memory, in the CA1 region of the hippocampus. Additionally, treatment of <i>Tsc2<sup>+/-</sup></i> mice with Memantine showed a trend towards restoration of the ability to locate the platform in the Morris water maze, a neurobehavioral test of hippocampal memory. In Year 02, we plan to further validate and extend our findings with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an advantage over Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders.         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       18. NUMBER OF RESPONSIBLE PERSON USAMRMC.         a. REPORT       b. ABSTRACT       c. THIS PAGE       18. NUMBER (include aree)							
The quality of life for those afflicted by Tuberous Sclerosis Complex (TSC) is affected by intellectual and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective therapies for early postnatal or even embryonic treatment of these neurological manifestations. Towards this goal, we propose to investigate if administration of the FDA-approved drug, Memantine, an uncompetitive/fast off-rate antagonist of the <i>N</i> - methyl-D-aspartate-type glutamate receptor, and its improved derivative, NitroMemantine, ameiorate neurological complications in mouse models of TSC. During Year 01 of the grant, we obtained favorable results for Memantine on electrophysiological and neurobehavioral tests in <i>Tsc2<sup>+/-</sup></i> mice. Treatment of <i>Tsc2<sup>+/-</sup></i> mice with Memantine improved long-term potentiation (LTP), an electrical correlate of learning and memory, in the CA1 region of the hippocampus. Additionally, treatment of <i>Tsc2<sup>+/-</sup></i> mice with Memantine showed a trend towards restoration of the ability to locate the platform in the Morris water maze, a neurobehavioral test of hippocampal memory. In Year 02, we plan to further validate and extend our findings with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an advantage over Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders.19a. NAME OF RESPONSIBLE PERSON USAMRMC16. SECURITY CLASSIFICATION OF:17. LIMITATION of ABSTRACT18. NUMBER of PAGES19a. NAME OF RESPONSIBLE PERSON USAMRMCa. REPORTb. ABSTRACTc. THIS PAGE17. LIMITATION OF ABSTRACT18. NUMBER OF DAGES19b. TELEPHONE NUMBER (include area	13. SUPPLEMENTARY NOTES						
The quality of life for those afflicted by Tuberous Sclerosis Complex (TSC) is affected by intellectual and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective therapies for early postnatal or even embryonic treatment of these neurological manifestations. Towards this goal, we propose to investigate if administration of the FDA-approved drug, Memantine, an uncompetitive/fast off-rate antagonist of the <i>N</i> - methyl-D-aspartate-type glutamate receptor, and its improved derivative, NitroMemantine, ameiorate neurological complications in mouse models of TSC. During Year 01 of the grant, we obtained favorable results for Memantine on electrophysiological and neurobehavioral tests in <i>Tsc2<sup>+/-</sup></i> mice. Treatment of <i>Tsc2<sup>+/-</sup></i> mice with Memantine improved long-term potentiation (LTP), an electrical correlate of learning and memory, in the CA1 region of the hippocampus. Additionally, treatment of <i>Tsc2<sup>+/-</sup></i> mice with Memantine showed a trend towards restoration of the ability to locate the platform in the Morris water maze, a neurobehavioral test of hippocampal memory. In Year 02, we plan to further validate and extend our findings with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an advantage over Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders.19a. NAME OF RESPONSIBLE PERSON USAMRMC16. SECURITY CLASSIFICATION OF:17. LIMITATION of ABSTRACT18. NUMBER of PAGES19a. NAME OF RESPONSIBLE PERSON USAMRMCa. REPORTb. ABSTRACTc. THIS PAGE17. LIMITATION OF ABSTRACT18. NUMBER OF DAGES19b. TELEPHONE NUMBER (include area							
The quality of life for those afflicted by Tuberous Sclerosis Complex (TSC) is affected by intellectual and neurological disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective therapies for early postnatal or even embryonic treatment of these neurological manifestations. Towards this goal, we propose to investigate if administration of the FDA-approved drug, Memantine, an uncompetitive/fast off-rate antagonist of the <i>N</i> - methyl-D-aspartate-type glutamate receptor, and its improved derivative, NitroMemantine, ameiorate neurological complications in mouse models of TSC. During Year 01 of the grant, we obtained favorable results for Memantine on electrophysiological and neurobehavioral tests in <i>Tsc2<sup>+/-</sup></i> mice. Treatment of <i>Tsc2<sup>+/-</sup></i> mice with Memantine improved long-term potentiation (LTP), an electrical correlate of learning and memory, in the CA1 region of the hippocampus. Additionally, treatment of <i>Tsc2<sup>+/-</sup></i> mice with Memantine showed a trend towards restoration of the ability to locate the platform in the Morris water maze, a neurobehavioral test of hippocampal memory. In Year 02, we plan to further validate and extend our findings with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an advantage over Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders.19a. NAME OF RESPONSIBLE PERSON USAMRMC16. SECURITY CLASSIFICATION OF:17. LIMITATION of ABSTRACT18. NUMBER of PAGES19a. NAME OF RESPONSIBLE PERSON USAMRMCa. REPORTb. ABSTRACTc. THIS PAGE17. LIMITATION OF ABSTRACT18. NUMBER OF DAGES19b. TELEPHONE NUMBER (include area	14 ABSTRACT						
disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective therapies for early postnatal or even embryonic treatment of these neurological manifestations. Towards this goal, we propose to investigate if administration of the FDA-approved drug, Memantine, an uncompetitive/fast off-rate antagonist of the <i>N</i> - methyl-D-aspartate-type glutamate receptor, and its improved derivative, NitroMemantine, ameliorate neurological complications in mouse models of TSC. During Year 01 of the grant, we obtained favorable results for Memantine on electrophysiological and neurobehavioral tests in <i>Tsc2<sup>+/-</sup></i> mice. Treatment of <i>Tsc2<sup>+/-</sup></i> mice with Memantine improved long-term potentiation (LTP), an electrical correlate of learning and memory, in the CA1 region of the hippocampus. Additionally, treatment of <i>Tsc2<sup>+/-</sup></i> mice with Memantine showed a trend towards restoration of the ability to locate the platform in the Morris water maze, a neurobehavioral test of hippocampal memory. In Year 02, we plan to further validate and extend our findings with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an advantage over Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders.19a. NAME OF RESPONSIBLE PERSON USAMRMC16. SECURITY CLASSIFICATION OF:17. LIMITATION OF ABSTRACT18. NUMBER OF PAGES19a. NAME OF RESPONSIBLE PERSON USAMRMCa. REPORTb. ABSTRACTc. THIS PAGE17. LIMITATION OF PAGES19a. NAME OF RESPONSIBLE PERSON USAMRMC							
to investigate if administration of the FDA-approved drug, Memantine, an uncompetitive/fast off-rate antagonist of the <i>N</i> - methyl-D-aspartate-type glutamate receptor, and its improved derivative, NitroMemantine, ameliorate neurological complications in mouse models of TSC. During Year 01 of the grant, we obtained favorable results for Memantine on electrophysiological and neurobehavioral tests in <i>Tsc2<sup>+/-</sup></i> mice. Treatment of <i>Tsc2<sup>+/-</sup></i> mice with Memantine improved long-term potentiation (LTP), an electrical correlate of learning and memory, in the CA1 region of the hippocampus. Additionally, treatment of <i>Tsc2<sup>+/-</sup></i> mice with Memantine showed a trend towards restoration of the ability to locate the platform in the Morris water maze, a neurobehavioral test of hippocampal memory. In Year 02, we plan to further validate and extend our findings with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an advantage over Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders. <b>15. SUBJECT TERMS</b> Excessive glutamatergic activity, Extrasynaptic NMDA receptors, Uncompetitive antagonist of NMDA receptors, Memantine, NitroMemantine <b>16. SECURITY CLASSIFICATION OF:</b> <b>17. LIMITATION</b> <b>18. NUMBER</b> <b>19a. NAME OF RESPONSIBLE PERSON</b> <b>USAMRMC</b> <b>19b. TELEPHONE NUMBER</b> <i>(include area</i> )	disabilities mediated in part by excessive glutamatergic activity in the brain. It is important to develop rational and effective						
methyl-D-aspartate-type glutamate receptor, and its improved derivative, NitroMemantine, ameliorate neurological complications in mouse models of TSC. During Year 01 of the grant, we obtained favorable results for Memantine on electrophysiological and neurobehavioral tests in $Tsc2^{+/-}$ mice. Treatment of $Tsc2^{+/-}$ mice with Memantine improved long-term potentiation (LTP), an electrical correlate of learning and memory, in the CA1 region of the hippocampus. Additionally, treatment of $Tsc2^{+/-}$ mice with Memantine showed a trend towards restoration of the ability to locate the platform in the Morris water maze, a neurobehavioral test of hippocampal memory. In Year 02, we plan to further validate and extend our findings with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an advantage over Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders.15. SUBJECT TERMS Excessive glutamatergic activity, Extrasynaptic NMDA receptors, Uncompetitive antagonist of NMDA receptors, Memantine, NitroMemantine18. NUMBER OF ABSTRACT19a. NAME OF RESPONSIBLE PERSON USAMRMCa. REPORTb. ABSTRACTc. THIS PAGE17. LIMITATION OF ABSTRACT18. NUMBER OF PAGES19a. NAME OF RESPONSIBLE PERSON USAMRMC							
complications in mouse models of TSC. During Year 01 of the grant, we obtained favorable results for Memantine on electrophysiological and neurobehavioral tests in $Tsc2^{+/-}$ mice. Treatment of $Tsc2^{+/-}$ mice with Memantine improved long-term potentiation (LTP), an electrical correlate of learning and memory, in the CA1 region of the hippocampus. Additionally, treatment of $Tsc2^{+/-}$ mice with Memantine showed a trend towards restoration of the ability to locate the platform in the Morris water maze, a neurobehavioral test of hippocampal memory. In Year 02, we plan to further validate and extend our findings with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an advantage over Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders.15. SUBJECT TERMS Excessive glutamatergic activity, Extrasynaptic NMDA receptors, Uncompetitive antagonist of NMDA receptors, Memantine, NitroMemantine16. SECURITY CLASSIFICATION OF:17. LIMITATION OF ABSTRACT18. NUMBER OF PAGES19a. NAME OF RESPONSIBLE PERSON USAMRMCa. REPORTb. ABSTRACTc. THIS PAGE17. LIMITATION OF ABSTRACT18. NUMBER OF PAGES19b. TELEPHONE NUMBER (include area							
electrophysiological and neurobehavioral tests in $Tsc2^{+/-}$ mice. Treatment of $Tsc2^{+/-}$ mice with Memantine improved long-term potentiation (LTP), an electrical correlate of learning and memory, in the CA1 region of the hippocampus. Additionally, treatment of $Tsc2^{+/-}$ mice with Memantine showed a trend towards restoration of the ability to locate the platform in the Morris water maze, a neurobehavioral test of hippocampal memory. In Year 02, we plan to further validate and extend our findings with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an advantage over Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders.15. SUBJECT TERMS Excessive glutamatergic activity, Extrasynaptic NMDA receptors, Uncompetitive antagonist of NMDA receptors, Memantine, NitroMemantine18. NUMBER OF ABSTRACT19a. NAME OF RESPONSIBLE PERSON USAMRMCa. REPORTb. ABSTRACTc. THIS PAGE17. LIMITATION OF ABSTRACT18. NUMBER OF PAGES19a. NAME OF RESPONSIBLE PERSON USAMRMC							
potentiation (LTP), an electrical correlate of learning and memory, in the CA1 region of the hippocampus. Additionally, treatment of <i>Tsc2</i> */- mice with Memantine showed a trend towards restoration of the ability to locate the platform in the Morris water maze, a neurobehavioral test of hippocampal memory. In Year 02, we plan to further validate and extend our findings with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an advantage over Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders.15. SUBJECT TERMS Excessive glutamatergic activity, Extrasynaptic NMDA receptors, Uncompetitive antagonist of NMDA receptors, Memantine, NitroMemantine18. NUMBER OF ABSTRACT19a. NAME OF RESPONSIBLE PERSON USAMRMCa. REPORTb. ABSTRACTc. THIS PAGE17. LIMITATION OF ABSTRACT18. NUMBER OF PAGES19b. TELEPHONE NUMBER (include area							
treatment of $Tsc2^{+/-}$ mice with Memantine showed a trend towards restoration of the ability to locate the platform in the Morris water maze, a neurobehavioral test of hippocampal memory. In Year 02, we plan to further validate and extend our findings with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an advantage over Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders.15. SUBJECT TERMS Excessive glutamatergic activity, Extrasynaptic NMDA receptors, Uncompetitive antagonist of NMDA receptors, Memantine, NitroMemantine16. SECURITY CLASSIFICATION OF:17. LIMITATION OF ABSTRACT18. NUMBER OF PAGES19a. NAME OF RESPONSIBLE PERSON USAMRMCa. REPORTb. ABSTRACTc. THIS PAGE17. LIMITATION OF ABSTRACT18. NUMBER OF PAGES19b. TELEPHONE NUMBER (include area							
with Memantine and critically test the efficacy of NitroMemantine. We expect that NitroMemantine will offer an advantage over         Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders.         15. SUBJECT TERMS         Excessive glutamatergic activity, Extrasynaptic NMDA receptors, Uncompetitive antagonist of NMDA receptors, Memantine, NitroMemantine         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT         a. REPORT       b. ABSTRACT         c. THIS PAGE       17. LIMITATION OF HIS PAGE							
Memantine in TSC model mice, as we have previously demonstrated in other neurological disorders.         15. SUBJECT TERMS Excessive glutamatergic activity, Extrasynaptic NMDA receptors, Uncompetitive antagonist of NMDA receptors, Memantine, NitroMemantine         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       18. NUMBER OF PAGES       19a. NAME OF RESPONSIBLE PERSON USAMRMC         a. REPORT       b. ABSTRACT       c. THIS PAGE       19b. TELEPHONE NUMBER (include area							
15. SUBJECT TERMS         Excessive glutamatergic activity, Extrasynaptic NMDA receptors, Uncompetitive antagonist of NMDA receptors, Memantine, NitroMemantine         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT         a. REPORT       b. ABSTRACT         c. THIS PAGE       17. LIMITATION OF ABSTRACT							
Excessive glutamatergic activity, Extrasynaptic NMDA receptors, Uncompetitive antagonist of NMDA receptors, Memantine, NitroMemantine         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT         a. REPORT       b. ABSTRACT         c. THIS PAGE       17. LIMITATION OF ABSTRACT							
NitroMemantine         16. SECURITY CLASSIFICATION OF:         a. REPORT         b. ABSTRACT         c. THIS PAGE             17. LIMITATION OF ABSTRACT             18. NUMBER OF PAGES             19a. NAME OF RESPONSIBLE PERSON             19. DELEPHONE NUMBER (include area)							
16. SECURITY CLASSIFICATION OF:     17. LIMITATION OF ABSTRACT     18. NUMBER OF PAGES     19a. NAME OF RESPONSIBLE PERSON USAMRMC       a. REPORT     b. ABSTRACT     c. THIS PAGE     19b. TELEPHONE NUMBER (include area							
of ABSTRACT         OF PAGES         USAMRMC           a. REPORT         b. ABSTRACT         c. THIS PAGE         19b. TELEPHONE NUMBER (include area			17. LIMITATION	18. NUMBER	19a. NAME OF RESPONSIBLE PERSON		
	a. REPORT	b. ABSTRACT	c. THIS PAGE		7		

### **Table of Contents**

### Page

Introduction	4
Overall Project Summary	4
Key Research Accomplishments	6
Reportable Outcomes	6
Conclusion	6
References	7
Appendices	7

## **1. INTRODUCTION:**

Tuberous sclerosis complex (TSC) is caused by heterozygous mutations that inactivate one of two genes, TSC1 or TSC2. The central nervous system is affected in TSC, and neurological manifestations include intellectual disabilities, neurobehavioral abnormalities such as autism, and epilepsy. Currently, there is no cure for TSC. The mechanism of pathogenesis is not entirely clear, but TSC-related neurological symptoms are accompanied by excessive glutamatergic activity and altered synaptic spine structures. Our group previously developed, characterized, and licensed patents for the drug Memantine (Namenda®), which is now FDA approved for treatment of moderate-to-severe Alzheimer's disease, showing that it is an uncompetitive/fast off-rate antagonist of the N-methyl-D-aspartate-type glutamate receptor (NMDAR). Interestingly, Memantine is also in clinical trials for children with epilepsy, intellectual disabilities, and autism. Additionally, we have recently developed a new series of derivatives, termed NitroMemantines, with superior efficacy to Memantine both in vitro and in vivo. Our recent work has demonstrated that Memantine and NitroMemantine selectively block excessive activity of extrasynaptic NMDARs (eNMDARs) and protect synaptic integrity. Furthermore, our phosphoproteomic analysis of eNMDAR-mediated signaling has identified upregulation of the p38 MAPK (mitogen-activated protein kinase)-MAPKAPK2 (mitogen-activated protein kinase-activated protein kinase 2) cascade. Since this pathway is known to inactivate TSC2, inhibition of eNMDARs with Memantine or NitroMemantine should increase TSC2 activity. Therefore, we hypothesized that this action of Memantine and NitroMemantine may offer a rational treatment for individuals with TSC. To begin to test this hypothesis, we thus proposed the following specific aim:

1. To investigate if Memantine or NitroMemantine administration improves synaptic spine structure, electrophysiological properties, and behavioral abnormalities in TSC murine models by affecting the eNMDAR/p38 MAPK/ MAPKAPK2/TSC2 cascade.

We proposed to examine if excessive eNMDAR activity and its downstream signaling cascade, which inhibits TSC2 activity, is a pathogenic mechanism in the development of synaptic spine abnormalities, electrophysiological abnormalities, and neurobehavioral manifestations in TSC. Also, we are investigating if the FDA-approved drug Memantine or the new improved derivative that we have synthesized, NitroMemantine, can alleviate synaptic spine and behavioral abnormalities in TSC murine models. Thus, this proposal will yield further mechanistic insight into the disease and evaluate new potential pharmaceutical approaches to treatment.

## 2. KEYWORDS:

Epilepsy, Intellectual disability, Autism, Excessive glutamatergic activity, Extrasynaptic NMDA receptors, Memantine, Uncompetitive antagonist of NMDA receptors, p38MAPK, MAPKAPK2, mTOR, p70 S6 kinase

#### **3. OVERALL PROJECT SUMMARY:**

Task 1. We will test the effect of Memantine vs. NitroMemantine in the  $Tsc1^{+/-}$  and  $Tsc2^{+/-}$  mouse models of TSC, including electrophysiological, histological, biochemical, and behavioral readouts (months 1-24)

#### **Results**

To fulfill the aim of this grant, we had proposed to obtain Tsc2 knockout mice from Jackson Laboratory. However, since the Jackson Laboratory possessed only frozen embryos, it was expected to take several months to have Tsc2 knockout mice from that source. Thus, we instead obtained the  $Tsc2^{+/+}$  and  $Tsc2^{+/-}$  mice from Dr. Mark F. Bear (MIT) (1). We initially had technical difficulties in genotyping following Dr. Bear's protocol that caused a delay of a couple of months before being able to begin breeding for the proposed experiments. As soon as we obtained  $Tsc2^{+/+}$  and  $Tsc2^{+/-}$  mice from our breeding colony, we first examined LTP (long-term potentiation) using field recordings in the CA1 region of hippocampal slices to investigate the effects of these mutations on synaptic plasticity. We prepared acute hippocampal slices from one-month old mice. We performed field recording in an MEA (microelectrode array) chamber perfused with ACSF (artificial cerebrospinal fluid). We recorded fEPSPs (field excitatory postsynaptic potentials) in the CA1 region with the MEA. We evoked LTP by stimulation of the Schaffer collaterals (four repetitions of 100 Hz pulses for one sec each). The initial slope of the fEPSP was analyzed to assess synaptic plasticity. As shown in **Fig. 1A** (see next page), we confirmed abnormality of LTP in  $Tsc2^{+/-}$  mice (2). Next, we found that treatment with 10  $\mu$ M Memantine over 4 hours produced a beneficial effect (**Fig. 1B**). Based on this result, we are now optimizing the dose and timing of Memantine treatment, and will then utilize theses optimized conditions to compare statistically the effects of Memantine versus NitroMemantine on improving LTP.



Fig. 1. Abnormal CA1-LTP in *Tsc2*<sup>+/-</sup> mice

(A) LTP recorded from hippocampal slices by MEA. Data are plotted every 30 sec and represent means  $\pm$  s.e.m. *Tsc2*<sup>+/+</sup>, *n* = 4 slices total from 4 mice; *Tsc2*<sup>+/-</sup>, *n* = 3 slices total from 3 mice. (B) Effect of Memantine treatment (10 µM incubation over 4 hours) on LTP in *Tsc2*<sup>+/-</sup> mice. 'Control' refers to treatment with vehicle rather than Memantine.

Next, to explore the effects of Memantine on the learning and memory deficits in  $Tsc2^{+/-}$  mice (2), we performed a behavioral readout, the Morris water maze test on three month-old  $Tsc2^{+/+}$  and  $Tsc2^{+/-}$  mice, as we had proposed. We administered Memantine intraperitoneally each day, 2 hours before the training sessions for that day. Mice received four training sessions per day for 5 consecutive days. We assessed spatial learning with a probe trial, during which mice swam for 60 sec. **Fig. 2A** shows representative tracking plots during the probe test. This initial set of tests demonstrated a strong trend that Memantine-treated  $Tsc2^{+/-}$  mice take a shorter time to reach the original platform location than do vehicle-treated  $Tsc2^{+/-}$  mice (**Fig. 2B**). In the coming grant year, we plan to increase the number of animals tested to see if this finding reaches statistical significance, as we had hypothesized. We will also determine the effects of the improved derivative,



# Fig. 2. Effect of Memantine treatment on the Morris water maze in $Tsc2^{+/-}$ mice

(A) Representative paths during a 60 sec probe test

(B) Time to reach the target platform location. Values are means  $\pm$  s.e.m.; n = 8 mice for  $Tsc2^{+/+}$ , n = 3 mice for  $Tsc2^{+/-}$ , n = 3 mice for  $Tsc2^{+/-}$  + Memantine.

NitroMemantine, on the Morris water maze test in  $Tsc2^{+/-}$  mice. For histological and molecular evaluation, we are collecting brain samples after the Morris water maze test to examine synaptic density and biochemical activity of the eNMDAR/p38 MAPK/MAPKAPK2/TSC2/mTORC1 cascade, as we had proposed in the original application.

#### **Progress and Accomplishments with Discussion**

The goal of this project is to determine if administration of the FDA-approved drug Memantine and its improved derivative, NitroMemantine, mitigates neurological manifestations in mouse models of TSC. A technical issue in genotyping of TSC mice caused a delay in the initiation of the experiments. However, once up and running, during Year 01 of the grant, we obtained favorable effects of Memantine on electrophysiology and behavior in  $Tsc2^{+/-}$  mice, as described above in the Results section. In Year 02, we plan to further validate and extend our findings on Memantine by utilizing electrophysiological, histological, biochemical, and behavioral approaches as proposed in the original grant application. Additionally, we will test the efficacy of NitroMemantine, as we had proposed in the original application. We expect that NitroMemantine will offer additional benefit over Memantine in TSC model mice because we recently found that NitroMemantine provided synaptic protection and rescued behavioral abnormalities to a greater extent than Memantine in Alzheimer's mouse models (3).

#### 4. KEY RESEARCH ACCOMPLISHMENTS

- Memantine treatment can restore to synaptic plasticity in  $Tsc2^{+/-}$  mice, as monitored by recording LTP.
- Memantine treatment shows promise in ameliorating deficits in learning and memory in *Tsc2*<sup>+/-</sup> mice, as monitored in the Morris water maze neurobehavioral test.

### **5. CONCLUSION**

The results from this proposal will have a major impact on medical treatment because they have the potential to initiate new treatments for the neurological manifestations of TSC, which are thought to be mediated in part by excessive glutamatergic activity in the brain. To this end, we are testing the FDA-approved drug Memantine, which our group played a major role in developing for other neurological indications, as well as our improved derivatives, termed NitroMemantines. Since the quality of life for those with TSC is most affected by intellectual and neurological disabilities, it is important that we understand the pathogenesis of early cognitive deficits in order to develop rational and effective therapies for early postnatal or even embryonic treatment of TSC. Hence, we are hopeful that children with TSC will benefit from the research proposed here via development of new drug therapies to increase their cognitive capacity and mitigate neurobehavioral abnormalities. Our initial results from treating  $Tsc2^{+/-}$  mice demonstrate promising beneficial effects. During Year 02, we plan to confirm and extend our findings with Memantine and also test the efficacy of the improved analog, NitroMemantine.

#### 6. PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS:

Nothing to report.

#### 7. INVENTIONS, PATENTS, AND LICENSES:

Nothing to report.

#### 8. REPORTABLE OUTCOMES;

Treatment of TSC2 heterozygote mice with 10 µM Memantine for 4 hours improved long-term potentiation (LTP) in the CA1 region of the hippocampus. Previously, it had been shown that LTP, an electrical correlate of learning and memory, was decreased in TSC2 heterozygote mice. We now report that treatment with Memantine (Namenda®), an FDA—approved drug that had been developed in our laboratory and licensed to Forest Laboratories in NYC, resulted in an increase in LTP in these mice. Additionally, TSC2 heterozygous mice show a decrement in Morris water maze activity, a neurobehavioral test of hippocampal memory. Treatment with Memantine showed a trend towards restoration of normal memory in these mice. In Year 02,

larger cohorts of mice and optimization of the treatment paradigm are planned in order to perform a rigorous statistical analysis of the results of these memory tests.

## 9. OTHER ACHIEVEMENTS:

Nothing to report.

# **10. REFERENCES:**

- 1. Auerbach BD, Osterweil EK, Bear MF. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature. 2011;480(7375):63-8. PMID: 22113615; PMCID: PMC3228874.
- 2. Gkogkas C, Sonenberg N, Costa-Mattioli M. Translational control mechanisms in long-lasting synaptic plasticity and memory. J Biol Chem. 2010;285(42):31913-7. PMID: 20693284; PMCID: PMC2952191.
- Talantova M, Sanz-Blasco S, Zhang X, Xia P, Akhtar MW, Okamoto S-I, Dziewczapolski G, Nakamura T, Cao G, Pratt AE, Kang Y-J, Tu S, Molokanova E, McKercher SR, Hires A, Sason H, Stouffer DG, Buczynski MW, Solomon J, Michael S, Powers ET, Kelly JW, Roberts AJ, Tong G, Fang-Newmeyer T, Parker J, Holland EA, Zhang D, Nakanishi N, Chen H-SV, Wolosker H, Parsons LH, Ambasudhan R, Masliah E, Heinemann SF, Piña-Crespo JC, Lipton SA. Aß induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A. 2013;110(27):E2518-27. PMID: 23776240; PMCID: PMC3704025.

# **11. APPENDICES:**

N/A